Literature DB >> 30880339

Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis.

Ting Shi1, Angeline Denouel2, Anna K Tietjen1, Iain Campbell1, Emily Moran1, Xue Li1, Harry Campbell1, Clarisse Demont2, Bryan O Nyawanda3, Helen Y Chu4, Sonia K Stoszek5, Anand Krishnan6, Peter Openshaw7, Ann R Falsey8,9, Harish Nair1,9.   

Abstract

Respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) constitutes a substantial disease burden in older adults aged ≥65 years. We aimed to identify all studies worldwide investigating the disease burden of RSV-ARI in this population. We estimated the community incidence, hospitalization rate, and in-hospital case-fatality ratio (hCFR) of RSV-ARI in older adults, stratified by industrialized and developing regions, using data from a systematic review of studies published between January 1996 and April 2018 and 8 unpublished population-based studies. We applied these rate estimates to population estimates for 2015 to calculate the global and regional burdens in older adults with RSV-ARI in the community and in hospitals for that year. We estimated the number of in-hospital deaths due to RSV-ARI by combining hCFR data with hospital admission estimates from hospital-based studies. In 2015, there were about 1.5 million episodes (95% confidence interval [CI], .3 million-6.9 million) of RSV-ARI in older adults in industrialized countries (data for developing countries were missing), and of these, approximately 14.5% (214 000 episodes; 95% CI, 100 000-459 000) were admitted to hospitals. The global number of hospital admissions for RSV-ARI in older adults was estimated at 336 000 hospitalizations (uncertainty range [UR], 186 000-614 000). We further estimated about 14 000 in-hospital deaths (UR, 5000-50 000) related to RSV-ARI globally. The hospital admission rate and hCFR were higher for those aged ≥65 years than for those aged 50-64 years. The disease burden of RSV-ARI among older adults is substantial, with limited data from developing countries. Appropriate prevention and management strategies are needed to reduce this burden.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Respiratory syncytial virus; acute respiratory infection; disease burden; older adults

Year:  2020        PMID: 30880339     DOI: 10.1093/infdis/jiz059

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  56 in total

1.  Estimating Transmission Parameters for Respiratory Syncytial Virus and Predicting the Impact of Maternal and Pediatric Vaccination.

Authors:  Michiel van Boven; Anne C Teirlinck; Adam Meijer; Mariëtte Hooiveld; Christiaan H van Dorp; Rachel M Reeves; Harry Campbell; Wim van der Hoek
Journal:  J Infect Dis       Date:  2020-10-07       Impact factor: 5.226

2.  TIPICO XI: report of the first series and podcast on infectious diseases and vaccines (aTIPICO).

Authors:  Federico Martinón-Torres; Adolfo García-Sastre; Andrew J Pollard; Carlos Martín; Albert Osterhaus; Shamez N Ladhani; Octavio Ramilo; Jose Gómez Rial; Antonio Salas; F Xavier Bosch; María Martinón-Torres; Michael J Mina; James Cherry
Journal:  Hum Vaccin Immunother       Date:  2021-11-11       Impact factor: 3.452

Review 3.  Ribavirin for Treatment of Subjects with Respiratory Syncytial Virus-Related Infection: A Systematic Review and Meta-Analysis.

Authors:  Sofia Tejada; Raquel Martinez-Reviejo; Hanife N Karakoc; Yolanda Peña-López; Oriol Manuel; Jordi Rello
Journal:  Adv Ther       Date:  2022-07-25       Impact factor: 4.070

4.  A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.

Authors:  Antonios O Aliprantis; Christine A Shaw; Paul Griffin; Nicholas Farinola; Radha A Railkar; Xin Cao; Wen Liu; Jeffrey R Sachs; Christine J Swenson; Heather Lee; Kara S Cox; Daniel S Spellman; Colleen J Winstead; Igor Smolenov; Eseng Lai; Tal Zaks; Amy S Espeseth; Lori Panther
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

Review 5.  The journey to a respiratory syncytial virus vaccine.

Authors:  Asuncion Mejias; Rosa Rodríguez-Fernández; Silvia Oliva; Mark E Peeples; Octavio Ramilo
Journal:  Ann Allergy Asthma Immunol       Date:  2020-03-23       Impact factor: 6.347

6.  A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas.

Authors:  Brittani N Blunck; Letisha Aideyan; Xunyan Ye; Vasanthi Avadhanula; Laura Ferlic-Stark; Lynn Zechiedrich; Brian E Gilbert; Pedro A Piedra
Journal:  Vaccine       Date:  2021-01-26       Impact factor: 3.641

Review 7.  Pathophysiology of COVID-19: Why Children Fare Better than Adults?

Authors:  Nitin Dhochak; Tanu Singhal; S K Kabra; Rakesh Lodha
Journal:  Indian J Pediatr       Date:  2020-05-14       Impact factor: 1.967

8.  Risk of Transmission and Viral Shedding From the Time of Infection for Respiratory Syncytial Virus in Households.

Authors:  Hirono Otomaru; Johanna Beulah T Sornillo; Taro Kamigaki; Samantha Louise P Bado; Michiko Okamoto; Mariko Saito-Obata; Marianette T Inobaya; Edelwisa Segubre-Mercado; Portia P Alday; Mayuko Saito; Veronica L Tallo; Beatriz P Quiambao; Hitoshi Oshitani; Alex R Cook
Journal:  Am J Epidemiol       Date:  2021-12-01       Impact factor: 4.897

Review 9.  Seaweed Sulfated Polysaccharides against Respiratory Viral Infections.

Authors:  Mehwish Jabeen; Mélody Dutot; Roxane Fagon; Bernard Verrier; Claire Monge
Journal:  Pharmaceutics       Date:  2021-05-16       Impact factor: 6.321

Review 10.  Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population.

Authors:  Laura M Stephens; Steven M Varga
Journal:  Vaccines (Basel)       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.